Scarica l'app Stockscreener
15.79
2.75%
0.49
Precedente Chiudi:
$15.30
Aprire:
$15.37
Volume 24 ore:
188.31K
Relative Volume:
0.30
Capitalizzazione di mercato:
$1.09B
Reddito:
$1.23M
Utile/perdita netta:
$-214.90M
Rapporto P/E:
-3.8305
EPS:
-4.1222
Flusso di cassa netto:
$-151.25M
1 W Prestazione:
+1.48%
1M Prestazione:
-7.37%
6M Prestazione:
-34.55%
1 anno Prestazione:
-40.59%
Intervallo 1D:
$15.37
$16.10
Intervallo di 1 settimana:
$14.97
$16.61
Portata 52W:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.88 | 1.09B | 1.23M | -214.90M | -151.25M | -4.1222 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.39 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.01 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.72 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
541.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan
Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise
Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conferences | SYRE Stock News - GuruFocus
Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World
BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance
First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World
Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks
Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus
Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter
MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World
Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq
Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire
Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spyre Therapeutics Inc Azioni (SYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
1.80%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):